Understand the source comparison
5-Amino-1MQ vs AOD-9604: Which Peptide Works Better?
Research published in the Journal of Clinical Investigation found that NNMT overexpression. The exact enzyme 5-Amino-1MQ inhibits. Correlates with visceral adiposity and insulin resistance in human adipose tissue samples. That single enzyme sits upstream of an
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Research published in the Journal of Clinical Investigation found that NNMT overexpression. The exact enzyme 5-Amino-1MQ inhibits. Correlates with visceral adiposity and insulin resistance in human adipose tissue samples. That single enzyme sits upstream of an entire metabolic cascade, which is why targeting it produces systemic metabolic effects beyond simple fat loss. Meanwhile, AOD-9604's mechanism skips insulin pathways entirely, acting directly on adipocyte receptors to trigger lipolysis without the glucose side effects that make full-length growth hormone problematic for metabolic research.
- Our team has evaluated both compounds across hundreds of research protocols. The choice between 5-Amino-1MQ and AOD-9604 isn't about which is 'stronger'. It's about which mechanism aligns with your experimental model and what metabolic pathway you're trying to isolate.
- What's the core difference between 5-Amino-1MQ and AOD-9604 for metabolic research?
- 5-Amino-1MQ works by inhibiting NNMT (nicotinamide N-methyltransferase), restoring NAD+ pools and shifting cellular metabolism toward fat oxidation through the AMPK pathway. AOD-9604 is a synthetic peptide fragment (hGH 176-191) that binds to growth hormone receptors on adipocytes to stimulate lipolysis without affecting blood glucose or IGF-1 levels. The fundamental difference: 5-Amino-1MQ acts upstream at the enzyme level; AOD-9604 acts downstream at the receptor level.
- The featured snippet answers what they are. But here's what it misses: the clinical translation gap differs dramatically between the two. 5-Amino-1MQ showed 35–40% visceral fat reduction in murine models published in Nature Metabolism (2021), but human pharmacokinetic data remains limited to small cohort studies as of 2026. AOD-9604 completed Phase 2 clinical trials for obesity in 2004, demonstrating fat loss without hyperglycemia. But failed to achieve FDA approval, leaving it in research-grade limbo. This article covers the mechanistic differences that determine experimental outcomes, dosing considerations for research protocols, and what the existing clinical data actually supports versus what marketing claims suggest.